I thought PYC's study for Retinitis Pigmentosa type 11 had a primary focus, namely to halt this blinding eye disease, (RP11), from progressing further, this in itself would be an amazing outcome if proven clinically successful.
In my opinion, today's announcement could be perceived by the market that our primary purpose could be to IMPROVE vision for those with RP11 and if read that way, potential new shareholders may not be appreciating our early efficacy data.
I would have preferred for PYC to have structured this announcement slightly different. I think it would've sounded much better if PYC was informing the market that latest visual testing of patients was providing early efficacy data to support an upcoming registrational trial designed to halt the progression of RP11 AND that some patients have already demonstrated visual improvements which could support the potential for even better results than initially being sought.
PYC Price at posting:
10.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)